KYNB:NASDAQ
Kyntra Bio Inc
6,13 USD
0,00%
(0,00) 1D
7-окт., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Mkt. cap
24,82 млн
Avg. vol.
25,57 миң
Volume
25,00
P/E ratio
0,14
52-wk high
9,70 USD
52-wk low
5,62 USD
EPS
45,30 USD
Beta
1,05
Shares outstanding
4,05 млн
No. of employees
34
Mkt. cap
24,82 млн
Avg. vol.
25,57 миң
Volume
25,00
P/E ratio
0,14
52-wk high
9,70 USD
52-wk low
5,62 USD
EPS
45,30 USD
Beta
1,05
Shares outstanding
4,05 млн
No. of employees
34
News stories
From web sources and news partners
AD HOC NEWS
·
4 саат мурун
Kyntra Bio sought Nasdaq review and Kyntra Bio stock costs EUR 5.45
Investing.com Canada
·
1 күн мурун
Form 4 Kyntra Bio Inc For: 6 October By Investing.com
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
Founded1993-ж., 1-янв.
HeadquartersСан Франциско, Калифорния, Америка Кошмо Штаттары
Sector-
Websitekyntrabio.com